Abbott unveils Atrasentan Phase 2 study results
Abbott‘s Atrasentan Phase 2 study was a double-blind, dose-ranging, placebo-controlled study of subjects with diabetic nephropathy on stable doses of renin-angiotensin system (RAS) inhibitors for more than 2
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.